Pin your most used calculators here by clicking the star in the dropdown.
Oncotype DX Interpreter
Clinical Context & Background
The Oncotype DX Breast Recurrence Score test predicts the benefit of chemotherapy in ER+, HER2- early breast cancer. This tool interprets the score based on age and nodal status, referencing pivotal data from the TAILORx (Node Negative) and RxPONDER (Node Positive 1-3) trials.
Formula Logic
Lookup based on Score (0-100), Age, and Nodal Status.Reference Data
| RS Range | Nodal Status | Chemo Benefit |
|---|---|---|
| 0 - 25 | N0 (Age > 50) | No Benefit |
| 0 - 15 | N0 (Age ≤ 50) | No Benefit |
| 16 - 25 | N0 (Age ≤ 50) | Some Benefit (~6-9% in 21-25 range) |
| 26 - 100 | Any | Clear Benefit |
| 0 - 25 | N1 (1-3 nodes) | Premenopausal: Benefit. Postmenopausal: No Benefit. |
Evidence-based oncology decision support. Verify with clinical guidelines.